Who Generates Higher Gross Profit? Takeda Pharmaceutical Company Limited or Arrowhead Pharmaceuticals, Inc.

Takeda vs. Arrowhead: A Decade of Gross Profit Dominance

__timestampArrowhead Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141750001256834000000
Thursday, January 1, 20153820001271973000000
Friday, January 1, 20161583331173296000000
Sunday, January 1, 2017314077091274610000000
Monday, January 1, 2018161423211437534000000
Tuesday, January 1, 20191687955772201424000000
Wednesday, January 1, 2020879920662203504000000
Friday, January 1, 20211382870002462160000000
Saturday, January 1, 20222328100002783406000000
Sunday, January 1, 20232407350002832257000000
Monday, January 1, 202435510002832257000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Pharmaceuticals: Gross Profit Analysis

In the competitive world of pharmaceuticals, understanding who leads in profitability can offer valuable insights. Over the past decade, Takeda Pharmaceutical Company Limited has consistently outperformed Arrowhead Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, Takeda's gross profit has shown a robust upward trend, peaking at approximately 2.83 trillion in 2023. In contrast, Arrowhead's gross profit, while growing, remains significantly lower, reaching around 240 million in the same year.

Takeda's dominance is evident, with its gross profit being over 10,000 times greater than Arrowhead's in 2023. This stark difference highlights Takeda's strong market position and operational efficiency. As the pharmaceutical industry continues to evolve, these financial insights provide a glimpse into the strategic maneuvers of these two companies, offering a fascinating perspective on their financial health and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025